Quest Diagnostics stock gains on Apple Health lab testing partnership

Published on 09/10/2026 at 19:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock closed at USD 235.50 on the New York Stock Exchange on September 8, 2026, 0.69 percent below the prior close as investors digested new Apple Health app lab testing integration. The company also projects earnings growth, with diluted EPS at 9.42 dollars over the trailing twelve months.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock (ISIN US74834L1008) closed at USD 235.50 on the New York Stock Exchange on September 8, 2026, down 0.69 percent from the previous close of USD 237.14 per recent price data, while investors weighed a new consumer health partnership with Apple Health.

Apple Health integration expands consumer lab access

As Moomoo reported on September 9, 2026, Quest Diagnostics announced that Apple Health app users in the United States will be able to purchase a tailored Quest laboratory test panel including over 50 biomarkers directly through the app later this year.

According to Moomoo, the Quest laboratory panel is priced at USD 119 and can be scheduled at approximately 2,000 Quest Diagnostics patient service centers, underscoring the scale of the company’s consumer-facing network as it pushes deeper into preventive health testing.

Earnings profile and growth metrics

Per recent data compiled by Yahoo Finance, Quest Diagnostics generated revenue of USD 11.56 billion over the trailing twelve months, with net income attributable to common shareholders of USD 1.06 billion and a profit margin of 9.19 percent, highlighting a solid earnings base for its diagnostics franchise.

According to the same overview from Yahoo Finance, diluted EPS over the trailing twelve months stands at USD 9.42, and the trailing price-earnings ratio is 24.49, implying that the stock trades at roughly 2.6 times its price-earnings multiple relative to its profit margin of 9.19 percent, a relationship investors often monitor when assessing valuation versus profitability.

Based on the same data snapshot from Yahoo Finance, Quest Diagnostics reports total cash of USD 626 million and levered free cash flow of USD 909.63 million, while total debt to equity stands at 81.07 percent, indicating that the company combines a meaningful cash generation profile with a moderate leverage level that investors will factor into risk assessments.

Valuation, dividend and upcoming dates

According to Yahoo Finance, Quest Diagnostics carries an intraday market capitalization of USD 25.498 billion as of early September 2026 and a price-sales ratio of 2.29 on trailing twelve-month revenue, suggesting that the stock is valued at a little over two times its annual sales base.

The same source from Yahoo Finance indicates a forward annual dividend of USD 3.44 per share, corresponding to a forward dividend yield of 1.46 percent, alongside a scheduled earnings date on October 20, 2026 and an ex-dividend date on October 6, 2026, giving shareholders clear upcoming checkpoints for income and new financial disclosures.

Stock level and trading range

Quest Diagnostics stock’s recent trading range has been relatively broad: per the same price overview from Yahoo Finance, the shares have traded between a 52-week low of USD 171.18 and a 52-week high of USD 247.19, placing the September 8, 2026 close of USD 235.50 roughly 37.5 percent above the low and 4.7 percent below the high based on these levels.

On the same as-of snapshot from Yahoo Finance, Quest Diagnostics showed a day’s range between USD 230.22 and USD 236.48, with volume of 485,554 shares against an average volume of 957,062 shares, indicating that current trading activity is somewhat lighter than typical daily turnover even as the stock remains near the upper end of its 52-week band.

Closing price and investor takeaway

At the closing price of USD 235.50 on the New York Stock Exchange as of September 8, 2026, Quest Diagnostics stock trades within a few percent of its 52-week high in USD, reflecting how investors are currently balancing the Apple Health app lab testing partnership and the company’s trailing twelve-month EPS of USD 9.42 against its valuation of about USD 25.5 billion.